Gilead Sciences (NASDAQ:GILD) had its price target hoisted by equities research analysts at SunTrust Banks from $73.00 to $74.00 in a research report issued on Friday, Briefing.com Automated Import reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. SunTrust Banks’ price target would indicate a potential upside of 6.43% from the company’s previous close.
A number of other equities analysts have also commented on GILD. UBS Group lowered Gilead Sciences from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $77.00 to $80.00 in a research note on Monday, April 27th. Cowen reissued a “buy” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Monday, April 13th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $85.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 28th. Cantor Fitzgerald boosted their price objective on Gilead Sciences from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 7th. Finally, DZ Bank reissued a “buy” rating on shares of Gilead Sciences in a research note on Monday, June 15th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and nine have assigned a buy rating to the company. Gilead Sciences has a consensus rating of “Hold” and an average target price of $79.63.
GILD opened at $69.53 on Friday. The stock has a market cap of $87.22 billion, a PE ratio of -289.70, a P/E/G ratio of 2.34 and a beta of 0.70. The company has a current ratio of 3.04, a quick ratio of 2.92 and a debt-to-equity ratio of 1.00. Gilead Sciences has a 1 year low of $60.89 and a 1 year high of $85.97. The stock’s 50 day simple moving average is $75.47 and its 200-day simple moving average is $73.57.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.57 by ($0.46). The company had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.24 billion. Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 32.17%. Equities analysts forecast that Gilead Sciences will post 6.79 earnings per share for the current fiscal year.
In other Gilead Sciences news, CAO Diane E. Wilfong sold 12,264 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $80.09, for a total value of $982,223.76. Following the completion of the sale, the chief accounting officer now directly owns 23,685 shares in the company, valued at $1,896,931.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 13,210 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $79.23, for a total value of $1,046,628.30. Following the completion of the sale, the executive vice president now owns 27,204 shares of the company’s stock, valued at $2,155,372.92. The disclosure for this sale can be found here. Insiders sold 28,079 shares of company stock valued at $2,240,630 over the last 90 days. Corporate insiders own 0.13% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Baldwin Brothers Inc. MA increased its holdings in shares of Gilead Sciences by 63.3% in the first quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 136 shares in the last quarter. Bainco International Investors acquired a new stake in shares of Gilead Sciences in the first quarter valued at approximately $29,000. EPG Wealth Management LLC lifted its position in shares of Gilead Sciences by 186.7% in the first quarter. EPG Wealth Management LLC now owns 410 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 267 shares during the last quarter. Modus Advisors LLC acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $38,000. Finally, Regal Wealth Group Inc. lifted its position in shares of Gilead Sciences by 400.0% in the second quarter. Regal Wealth Group Inc. now owns 500 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 400 shares during the last quarter. Institutional investors own 78.74% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: Derivative
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.